Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rivastigmine · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| Rivastigmine | EXPERIMENTAL | Rivastigmine capsules 1.5 mg of Dr.Reddy's Laboratories Limited |
| exelon | ACTIVE_COMPARATOR | Exelon 1.5 mg capsules of Novartis |
| Name | Type | Description |
|---|---|---|
| Rivastigmine | DRUG | Rivastigmine 1.5 mg Capsules |
Inclusion criteria * Subjects enrolled in this study will be members of the community at large. The recruitment advertisements may use various media types (e.g. radio, newspaper, Anapharm Inc. Web site, Anapharm Inc. volunteer's database). Subjects must meet all of the following criteria in order t...
Rivastigmine is a small molecule drug being developed by Dr. Reddy's Laboratories Ltd. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers in bioequivalence trials.
Rivastigmine has been studied in healthy volunteers in clinical trials. The trials were bioequivalence studies, which are designed to compare the drug's absorption and effects with a reference product. The drug is not yet approved for any specific medical condition.
Rivastigmine is being developed by Dr. Reddy's Laboratories Ltd, a pharmaceutical company listed on the stock exchange under the ticker RDY. The company has conducted clinical trials to evaluate the drug's bioequivalence in healthy subjects.
Rivastigmine is in Phase 1 clinical development. Two Phase 1 trials have been completed, both involving healthy volunteers. The drug is investigational and has not been approved by regulatory authorities.
Rivastigmine has been studied in two completed Phase 1 clinical trials: NCT01146041, a bioequivalence study of Rivastigmine capsules 1.5 mg under fed conditions, and NCT01146067, a bioequivalence study of Rivastigmine 1.5 mg capsules under fasting conditions. Each trial enrolled 44 healthy participants.
Rivastigmine is the generic name for a drug that is also known by the brand name Exelon. The clinical trials conducted by Dr. Reddy's Laboratories Ltd evaluated the bioequivalence of Rivastigmine capsules compared to a reference product.